Navigation Links
Cepheid Announces FDA Clearance of Next-Generation Test for MRSA Colonization
Date:12/19/2016

SUNNYVALE, Calif., Dec. 19, 2016 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for Xpert® MRSA NxG, the next generation methicillin-resistant Staphylococcus aureus (MRSA) infection control test from the leader in healthcare-associated infection (HAI) testing. Xpert® MRSA NxG is an accurate, on-demand, molecular test that delivers actionable results in about an hour.

MRSA has been an infection prevention challenge for over a decade, during which, new strains have emerged, often escaping detection by conventional assays and threatening the substantial gains made in HAI prevention in recent years1. To meet this challenge, Xpert MRSA NxG was developed utilizing an extensive library of MRSA strains collected from around the world and demonstrates unprecedented strain coverage. Integral to the new test design are updated PCR primers and probes that detect both mecA and mecC strains, which reduces the frequency of false-positive results due to "empty cassette" strains. The test has been validated for use with both ESwab™ (Copan) and rayon swabs.2

"MRSA surveillance remains a critical infection prevention activity for healthcare facilities and one that is challenged by the continued evolution of target sequences within MRSA," said Dr. Fred C. Tenover, Cepheid's Vice President for Scientific Affairs. "Fortunately, our global MRSA surveillance initiative has helped us keep ahead of the curve by alerting us to the emergence of novel strain types, enabling us to design a more comprehensive assay that takes into account major shifts, like the emergence of mecC, as well as more subtle changes in the SCCmec targets."

Active surveillance testing using rapid molecular diagnostics, along with standard infection prevention practices, have been shown to reduce the spread of MRSA in healthcare settings3. Studies have shown that MRSA screening programs using on-demand molecular tests contribute to:

  • Decreased MRSA infection rates in the ICU by 62%3
  • Reduced isolation days by 44%4
  • Decreased overall hospital costs4

Cepheid is committed to the fight against the spread of multidrug-resistant organisms. For information on our Diagnostics First education campaign, visit www.DiagnosticsFirst.com.  Xpert® MRSA NxG will begin shipping in December.  For more information on Cepheid's GeneXpert® Systems or the complete menu of Xpert tests, visit www.cepheidinternational.com

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com.

About GeneXpert Systems and Xpert Tests

With more than 11,000 systems in 182 countries, the GeneXpert System is the world's most popular molecular diagnostics' system.  The GeneXpert System's modular configuration means that the system is the most scalable available, offering the ability to perform from one to eighty Xpert tests at the same time.  As a result, the GeneXpert System meets the throughput requirements of customers of all sizes - from lower volume point-of-care settings to higher volume reference laboratories - enabling accurate, fast and cost effective test results.

GeneXpert Systems run proprietary Xpert test cartridges.  The Xpert test menu spans healthcare-associated infections, sexual health, critical infectious disease, and oncology, and today offers 24 tests outside the US, and 20 tests in the US.  More information on the GeneXpert System and the Xpert tests is available on our website at www.cepheid.com

References:

  1. Bal et al. Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated methicillin-resistant Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob Resist. 2016 6:95-101.
  2. Cepheid Xpert MRSA NxG Package Insert.
  3. Jain et al. Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med. 2011 364:1419-30.
  4. Wassenberg et al. Costs and benefits of rapid screening of methicillin-resistant Staphylococcus aureus carriage in intensive care units: a prospective multicenter study. Crit Care. 2012 16:R22.

Contact:
Darwa Peterson
+1 408-400-4324
Media.Communications@cepheid.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cepheid-announces-fda-clearance-of-next-generation-test-for-mrsa-colonization-300380874.html


'/>"/>
SOURCE Cepheid
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Why Investors Love These Scientific & Technical Instruments Stocks? - Trimble Navigation, Garmin, Cepheid, and Keysight Technologies
2. Cepheid Announces First FDA-Cleared Test for Detection of Carbapenem Resistance Genes in Isolates of Multidrug Resistant Superbugs
3. Cepheid Delivers Milestone 10,000th GeneXpert System
4. Cepheid Announces Appointment of President and Chief Operating Officer and Welcomes Executive Vice President of Engineering and Operations
5. Cepheid Reports Fourth Quarter And Full Year 2015 Results
6. Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases
7. Cepheid Announces Distribution Agreement with Henry Schein
8. Cepheid Receives FDA CLIA Waiver for Xpert Flu+RSV Xpress Test
9. Cepheid Supports Inaugural Antibiotic Awareness Week
10. Global BioMEMS and Microsystem Market in Healthcare 2015-2019 with Bluechiip, Cepheid, Given Imaging & Integrated Sensing Systems Dominating
11. Cepheid Reports 2015 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... Colo. , Aug. 10, 2017  Physical Rehabilitation Network ... located in Lakewood, Colorado . The reputable ... Jeff Lipkin , PT, DPT with his staff of four ... University of Pittsburgh and brings over 10 years of experience ... Belmar PT marks the 10th PRN clinic in ...
(Date:8/7/2017)... Md. , Aug. 7, 2017 ... healthcare member acquisition, retention, and engagement, announced the ... of Strategy and Product Development, effective as of ... consulting and technology implementation strategy for our clients. ... of experience in consulting and business analytics within ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus ... breastfeeding mothers. These illustrations show the diversity of the breastfeeding mothers, using ... wide range of sizes. These illustrations are also available on tote bags, notepads, ...
(Date:8/18/2017)... ... August 19, 2017 , ... ... Thailand presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, ... Noppadon Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand ...
(Date:8/18/2017)... York, NY (PRWEB) , ... August 18, 2017 ... ... launch of this summer’s edition of “Vision & Hearing,” advocating for active, healthy ... campaign focuses on resources available for individuals with hearing impairments and shares the ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... and asset protection assistance to communities in North-Central West Virginia, is embarking on ... to at-risk boys in the area. , The Chestnut Mountain Ranch (CMR) is ...
(Date:8/18/2017)... ... ... The Golseth Agency, a Texas based insurance management and financial planning assistance ... campaign organized to provide support to Christina Upchurch and her two children after the ... children returned from out of town to find her husband passed away and their ...
Breaking Medicine News(10 mins):